Agenus Inc. (Nasdaq: AGEN) will present three-year survival data from a Phase 1b clinical study of botensilimab (BOT) combined with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE